Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 3:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 3,379 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Comparator device Clear all
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of Intracanalicular Dexamethasone Compared to Loteprednol Etabonate in Patients With Keratoconus

NCT04418999
View directory record Official record
Conditions
Keratoconus, Dry Eye, Allergy
Interventions
dexamethasone ophthalmic insert 0.4 mg, for intracanalicular use, Loteprednol Etabonate 0.38% Ophthalmic Gel/Jelly
Drug
Lead sponsor
Illinois College of Optometry
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Oct 21, 2026, 3:59 PM EDT
Recruiting Phase 4 Interventional

Comparative Effectiveness of Available Treatments for Sinus and Ear Infections in Children (Acute Otitis Media)

NCT07730814
View directory record Official record
Conditions
Acute Otitis Media (AOM)
Interventions
Amoxicillin, Amoxicillin-Clavulanate, Amoxicillin Placebo, Amoxicillin-Clavulanate Placebo
Drug
Lead sponsor
Nader Shaikh
Other
Eligibility
6 Months to 36 Months
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
5
States / cities
Denver, Colorado • Durham, North Carolina • Cincinnati, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 21, 2026, 3:59 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Motor Imagery Exercise and Tongue Strength

NCT03423095
View directory record Official record
Conditions
Dysphagia
Interventions
Active Jaw Exercise with Relaxation, Active Tongue Exercise, Active Tongue Exercise + Mental Practice, Mental Practice Tongue Exercise
Behavioral
Lead sponsor
University of South Florida
Other
Eligibility
60 Years to 89 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Sarasota, Florida
Source: ClinicalTrials.gov public record
Updated Apr 17, 2019 · Synced Oct 21, 2026, 3:59 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Coffee Roasting on Blood Sugar Levels in Healthy Humans

NCT05119153
View directory record Official record
Conditions
Hyperglycemia
Interventions
Placebo Comparator, Light Roasted Coffee, Medium Roasted Coffee, Dark Roasted Coffee
Dietary Supplement
Lead sponsor
North Carolina State University
Other
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 12, 2021 · Synced Oct 21, 2026, 3:59 PM EDT
Recruiting Not applicable Interventional

Transcutaneous Auricular Vagus Nerve Stimulation for Insomnia in Survivors of Childhood Acute Lymphoblastic Leukemia

NCT07191119
View directory record Official record
Conditions
Survivor of Childhood Cancer, Insomnia, Acute Lymphoblastic Leukemia (ALL)
Interventions
Soterix tVNS device, Soterix tVNS device (sham programmed), Sleep Quality, Neurocognitive and mental health outcomes
Device · Behavioral
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
20 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 21, 2026, 3:59 PM EDT
Suspended Phase 2 Interventional

Novel Intervention for Chronic Complex TBI in OEF/OIF/OND Veterans

NCT05671692
View directory record Official record
Conditions
Traumatic Brain Injury, TBI
Interventions
Pregnenolone, Placebo
Drug
Lead sponsor
Christine Marx, MD
Other
Eligibility
21 Years to 65 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 21, 2026, 3:59 PM EDT
Completed Phase 1Phase 2 Interventional Results available

DBPC Trial to Evaluate the Safety, Tolerability and Efficacy of Oral Litoxetine in Subjects With Urinary Incontinence

NCT03397771
View directory record Official record
Conditions
Urinary Incontinence
Interventions
Litoxetine, placebo
Drug
Lead sponsor
Ixaltis SA
Industry
Eligibility
18 Years to 70 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Williamsville, New York
Source: ClinicalTrials.gov public record
Updated Jun 11, 2020 · Synced Oct 21, 2026, 3:59 PM EDT
Not yet recruiting Early Phase 1 Interventional Accepts healthy volunteers

Neuro-Intermuscular Coordination Enhancement (NICE) Rehabilitation Through Human-Machine Interaction in Chronic Stroke

NCT07531264
View directory record Official record
Conditions
Chronic Stroke-related Upper-extremity Motor Impairment, Motor Module-guided Rehabilitation Targeting Impaired Intermuscular Coordination and Motor Recovery
Interventions
Neuromuscular coordination enhancement (NICE) intervention, EMG Amplitude Biofeedback Exercise
Other
Lead sponsor
University of Houston
Other
Eligibility
21 Years to 80 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2027 – 2032
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 21, 2026, 3:59 PM EDT
Completed Not applicable Interventional

Glaucoma Management in the African-Derived Developing World Using Trabeculoplasty

NCT02375009
View directory record Official record
Conditions
Glaucoma
Interventions
Selective laser trabeculoplasty
Procedure
Lead sponsor
West Virginia University
Other
Eligibility
30 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Jun 18, 2021 · Synced Oct 21, 2026, 3:59 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Dorzolamide-timolol in Combination With Anti-vascular Endothelial Growth Factor Injections for Wet Age-related Macular Degeneration

NCT03034772
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration, Wet Macular Degeneration
Interventions
Dorzolamide-timolol, Artificial tears
Drug · Other
Lead sponsor
Wills Eye
Other
Eligibility
45 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
5
States / cities
Palo Alto, California • Boston, Massachusetts • Royal Oak, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2020 · Synced Oct 21, 2026, 3:59 PM EDT
Completed Phase 2 Interventional Results available

A Study in Patients With Erosive Esophagitis to Investigate Safety, Tolerability, and Healing Rates After 4 Weeks Treatment of X842 or Lansoprazole and Symptom Pattern During Subsequent 4 Weeks Treatment With Lansoprazole

NCT05055128
View directory record Official record
Conditions
Erosive Esophagitis
Interventions
X842, X842 Dummy, Lansoprazole, Lansoprazole Dummy
Drug
Lead sponsor
Cinclus Pharma Holding AB
Industry
Eligibility
18 Years to 75 Years
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 21, 2026, 3:59 PM EDT
Completed Phase 3 Interventional Results available

A Study of the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia.

NCT04115319
View directory record Official record
Conditions
Schizophrenia
Interventions
SEP363856, quetiapine XR
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
18
States / cities
Cerritos, California • Oakland, California • Oceanside, California + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2025 · Synced Oct 21, 2026, 3:59 PM EDT
Completed Phase 1 Interventional

Multiple Ascending Dose Study of CTI-1601 Versus Placebo in Subjects With Friedreich's Ataxia

NCT04519567
View directory record Official record
Conditions
Friedreich Ataxia
Interventions
CTI-1601, Placebo
Biological
Lead sponsor
Larimar Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Eatontown, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 30, 2021 · Synced Oct 21, 2026, 3:59 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Human Lung Responses to Respiratory Pathogens

NCT01967628
View directory record Official record
Conditions
Respiratory Infection
Interventions
Vitamin D3 (cholecalciferol), Placebo Sugar Pill
Dietary Supplement
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 60 Years
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Mar 29, 2018 · Synced Oct 21, 2026, 3:59 PM EDT
Completed Phase 2 Interventional Results available

Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy

NCT01496365
View directory record Official record
Conditions
Diabetic Peripheral Neuropathy
Interventions
DS-5565 tablet, pregabalin capsule, Placebo tablet, placebo capsule
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
78
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mesa, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 21, 2026, 3:59 PM EDT
Completed Phase 4 Interventional

Use of Ketorolac in Management of Post-Operative Pain After Heart Surgery

NCT00161577
View directory record Official record
Conditions
Pain Management Following Cardiopulmonary Bypass Surgery
Interventions
Ketorolac, Placebo
Drug · Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 13, 2009 · Synced Oct 21, 2026, 3:59 PM EDT
Completed Phase 2 Interventional Results available

KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)

NCT01626664
View directory record Official record
Conditions
Adult T-cell Leukemia-Lymphoma
Interventions
KW-0761, Pralatrexate, gemcitabine plus oxaliplatin, DHAP
Biological · Drug
Lead sponsor
Kyowa Kirin, Inc.
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
10
States / cities
Los Angeles, California • Miami, Florida • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2024 · Synced Oct 21, 2026, 3:59 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Assessing the PK and Effect on Glucose and GI Hormone Concentrations of Metformin Delayed-Release in Subjects With T2DM

NCT01677299
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
EFB0027 (metformin delayed release), EFB0026 (metformin immediate-release)
Drug
Lead sponsor
Elcelyx Therapeutics, Inc.
Industry
Eligibility
19 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
2
States / cities
Tempe, Arizona • Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 20, 2016 · Synced Oct 21, 2026, 3:59 PM EDT
Active, not recruiting Phase 3 Interventional

Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)

NCT05173987
View directory record Official record
Conditions
Endometrial Neoplasms
Interventions
pembrolizumab, carboplatin, paclitaxel, docetaxel, cisplatin
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
35
States / cities
Phoenix, Arizona • La Jolla, California • Riverside, California + 28 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 21, 2026, 3:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pivotal Bioequivalence Study of Topically Delivered Clobetasol Propionate Lotion in Healthy Adult Subjects

NCT00864500
View directory record Official record
Conditions
Healthy
Interventions
Clobetasol Propionate 0.05% lotion, single exposure, Clobex TM 0.05% Lotion, single exposure
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
224 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 9, 2019 · Synced Oct 21, 2026, 3:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Behavioral Effects of Drugs (Inpatient): 40 [Methamphetamine, Methylphenidate, Duloxetine]

NCT04178993
View directory record Official record
Conditions
Methamphetamine Use Disorder
Interventions
Methamphetamine, Methylphenidate, Placebo oral capsule, Duloxetine
Drug
Lead sponsor
Craig Rush
Other
Eligibility
18 Years to 55 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
2
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jan 9, 2023 · Synced Oct 21, 2026, 3:59 PM EDT
Completed Phase 2 Interventional Results available

Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT03776812
View directory record Official record
Conditions
Recurrent Ovarian Cancer, Recurrent Fallopian Tube Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Relacorilant, Nab-paclitaxel
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years and older · Female only
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
12
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Denver, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Oct 21, 2026, 3:59 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Phase III Study to Demonstrate the Safety and Efficacy of DWP-450 to Treat Glabellar Lines - EV-002

NCT02334436
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
Botulinum toxin, Type A, 0.9% sterile, unpreserved saline
Biological · Other
Lead sponsor
Evolus, Inc.
Industry
Eligibility
18 Years and older
Enrollment
324 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Beverly Hills, California
Source: ClinicalTrials.gov public record
Updated Mar 27, 2019 · Synced Oct 21, 2026, 3:59 PM EDT
Completed Phase 1 Interventional

Cough Desensitization Therapy: Pilot 2

NCT05226299
View directory record Official record
Conditions
Cough
Interventions
Supra-threshold and progressive doses of diluted capsaicin via a dosimeter-controlled nebulizer, Saline
Biological
Lead sponsor
University of Montana
Other
Eligibility
18 Years to 99 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Missoula, Montana
Source: ClinicalTrials.gov public record
Updated Nov 3, 2022 · Synced Oct 21, 2026, 3:59 PM EDT